355 related articles for article (PubMed ID: 26472107)
1. Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells.
Zhao Q; Assimopoulou AN; Klauck SM; Damianakos H; Chinou I; Kretschmer N; Rios JL; Papageorgiou VP; Bauer R; Efferth T
Oncotarget; 2015 Nov; 6(36):38934-51. PubMed ID: 26472107
[TBL] [Abstract][Full Text] [Related]
2. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways.
Chen Y; Zheng L; Liu J; Zhou Z; Cao X; Lv X; Chen F
Int Immunopharmacol; 2014 Aug; 21(2):447-55. PubMed ID: 24905636
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
Hahn M; Li W; Yu C; Rahmani M; Dent P; Grant S
Mol Cancer Ther; 2005 Mar; 4(3):457-70. PubMed ID: 15767555
[TBL] [Abstract][Full Text] [Related]
4. Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways.
Jing H; Sun W; Fan J; Zhang Y; Yang J; Jia J; Li J; Guo J; Luo S; Zheng Y
Mol Med Rep; 2016 Apr; 13(4):3009-16. PubMed ID: 26935874
[TBL] [Abstract][Full Text] [Related]
5. Reactive oxygen species-mediated activation of the Akt/ASK1/p38 signaling cascade and p21(Cip1) downregulation are required for shikonin-induced apoptosis.
Ahn J; Won M; Choi JH; Kim YS; Jung CR; Im DS; Kyun ML; Lee K; Song KB; Chung KS
Apoptosis; 2013 Jul; 18(7):870-81. PubMed ID: 23546866
[TBL] [Abstract][Full Text] [Related]
6. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway.
Yu C; Mao X; Li WX
Biochem Biophys Res Commun; 2005 Jun; 331(2):391-7. PubMed ID: 15850772
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Dai Y; Rahmani M; Pei XY; Khanna P; Han SI; Mitchell C; Dent P; Grant S
Blood; 2005 Feb; 105(4):1706-16. PubMed ID: 15494423
[TBL] [Abstract][Full Text] [Related]
9. Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-kappaB: neuroprotective implications.
Nam KN; Son MS; Park JH; Lee EH
Neuropharmacology; 2008 Oct; 55(5):819-25. PubMed ID: 18657551
[TBL] [Abstract][Full Text] [Related]
10. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
11. Shikonin inhibited mitogen-activated IL-4 and IL-5 production on EL-4 cells through downregulation of GATA-3 and c-Maf induction.
Lee CC; Kang JJ; Chiang BL; Wang CN; Cheng YW
Life Sci; 2011 Sep; 89(11-12):364-70. PubMed ID: 21806999
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells.
Mao X; Yu CR; Li WH; Li WX
Cell Res; 2008 Aug; 18(8):879-88. PubMed ID: 18663379
[TBL] [Abstract][Full Text] [Related]
13. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
Zhao Q; Kretschmer N; Bauer R; Efferth T
Int J Cancer; 2015 Sep; 137(6):1446-56. PubMed ID: 25688715
[TBL] [Abstract][Full Text] [Related]
14. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway.
Zhang Y; Chen HX; Zhou SY; Wang SX; Zheng K; Xu DD; Liu YT; Wang XY; Wang X; Yan HZ; Zhang L; Liu QY; Chen WQ; Wang YF
Mol Cancer; 2015 Mar; 14():56. PubMed ID: 25890196
[TBL] [Abstract][Full Text] [Related]
15. Shikonin suppresses proliferation and induces apoptosis in human leukemia NB4 cells through modulation of MAPKs and c‑Myc.
Shan ZL; Zhong L; Xiao CL; Gan LG; Xu T; Song H; Yang R; Li L; Liu BZ
Mol Med Rep; 2017 Sep; 16(3):3055-3060. PubMed ID: 28713949
[TBL] [Abstract][Full Text] [Related]
16. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Yu C; Rahmani M; Dent P; Grant S
Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752
[TBL] [Abstract][Full Text] [Related]
17. Shikonin inhibits the proliferation of human lens epithelial cells by inducing apoptosis through ROS and caspase-dependent pathway.
Huang WR; Zhang Y; Tang X
Molecules; 2014 Jun; 19(6):7785-97. PubMed ID: 24962386
[TBL] [Abstract][Full Text] [Related]
18. Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways.
Guo ZL; Li JZ; Ma YY; Qian D; Zhong JY; Jin MM; Huang P; Che LY; Pan B; Wang Y; Sun ZX; Liu CZ
BMC Cell Biol; 2018 Dec; 19(1):29. PubMed ID: 30594131
[TBL] [Abstract][Full Text] [Related]
19. Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells.
Liu SQ; Yu JP; Yu HG; Lv P; Chen HL
Dig Liver Dis; 2006 May; 38(5):310-8. PubMed ID: 16527552
[TBL] [Abstract][Full Text] [Related]
20. Early modifications in the expression of mitogen-activated protein kinase (MAPK/ERK), stress-activated kinases SAPK/JNK and p38, and their phosphorylated substrates following focal cerebral ischemia.
Ferrer I; Friguls B; Dalfó E; Planas AM
Acta Neuropathol; 2003 May; 105(5):425-37. PubMed ID: 12677442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
